BDKRB2 and Alzheimer disease: Immediately after the discovery of covalent AT2 receptor aggregation in AD (34, 35), the research on neurodegenerative GPCR aggregation in Alzheimer's disease was interrupted by a publication, which reported “lack of evidence for AT1R/B2R heterodimerization” (19).